Navigation Links
LifeCare Holdings, Inc. Announces Year-end Results
Date:3/28/2008

n in face of our senior subordinated notes for approximately $1.5 million. Partially offsetting the gain was the write-off of capitalized financing cost of $0.1 million recorded in connection with the retirement of these senior subordinated notes.

Excluding the impairment charge and the compensation and benefits accrual for 2007, and the impairment charge, gain on early extinguishment of debt, and the insurance recovery for 2006, expenses increased by $14.9 million from the same period in prior year. Rent expense increased by $3.6 million during the 2007 period in connection with the increases in bed capacity during 2007. Net interest expense increased by $3.1 million during the 2007 period as a result of an increase in the LIBOR rates during 2007 and in the margin spread as the result of the amendments to our senior secured credit facility discussed in the Liquidity and Capital Resources section below. The remaining $8.2 million increase in expenses was primarily attributable to an increase in salaries, wages and benefits of $8.3 million, and an increase in outside services, contract labor and other operating expenses of $3.1 million. These increases resulted from inflation and the increases in bed capacity during 2007. These increases were offset by a decrease in the provision for doubtful accounts of $2.9 million and a decrease in depreciation and amortization expense of $0.6 million. The provision for doubtful accounts during 2006 included an additional provision of $1.7 million for the impact of a conversion to a new patient accounting system during 2006.

Credit Agreement EBITDA

For the year-ended December 31, 2007, Credit Agreement EBITDA, was $47.5 million, including a $6 million cure amount discussed below, a decrease of $10.3 million, or 17.8% from the prior year period. The decrease in Credit Agreement EBITDA, on a dollar and percentage of net patient service revenue basis, was primarily due to the reduction in revenues associated with
'/>"/>

SOURCE LifeCare Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. LifeCare Hospitals of Wisconsin Unveils Center for Advanced Wound Healing
2. LifeCare Holdings, Inc. Announces Third Quarter Results
3. Batesville Holdings, Inc., Appoints Doug Wilson Senior Vice President Human Resources
4. Previously Disclosed Changes in Board Composition of NightHawk Radiology Holdings, Inc. Prompt Notice of Noncompliance from the Nasdaq Global Market
5. Solera Holdings, Inc. Appoints Jason Brady as General Counsel
6. Duane Reade Holdings, Inc. to Report Fourth Quarter and Full Year 2007 Financial Results
7. Whitemark Homes Signs Letter of Intent to Acquire Metiscan Holdings, Inc.
8. Vallon Holdings, LLC Launches New Subsidiary Focused on Contract Resources for the Minneapolis-St. Paul Life Science Industry
9. NightHawk Radiology Holdings, Inc. Announces Board Member Departure
10. NightHawk Radiology Holdings, Inc. to Speak at the Cowen and Company 28th Annual Health Care Conference on March 18, 2008
11. Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Proprietary Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...ogs have surprised researchers by showing that the...an toddlers. The study, by Austrian researchers,... when it comes to a physical problem-solving test....en researchers first observed how several children...
...tgrave, PhD, an expert on HIV prevention at the Jo...argeted campaign of testing and counseling aimed ...e effective than the mass patient screening propos...and Prevention (CDC). Holtgraves study is the fir...
...nday against South Korea's hard-drinking culture w...d economic losses, officials said . The campaign f...re to enhance public awareness of the dangers of e...ealth and Welfare said. "South Koreans consider o...
...heimer drug in the form of a milkshake. This milks...tarved by the damages of the Alzheimer disease . I...g large scale testing against the brain destroying...d Ketasyn, is a new approach to treating dementia....
Other Medicine News:Health News:Dogs Reasoning on Par With Human Toddlers: Study 2Health News:Targeted HIV Testing An Effective Way to Screen HIV Patients 2Health News:A Milky Alternative to Alzheimer Drug 2
(Date:9/3/2008)...ber is National Vascular Disease Awareness Month, ...fusion Pharmaceuticals,LLC, a clinical-stage drug-...the treatment of unmet medical needs, announced to...e I/II clinical trial of its lead drug,candidate t...ed NCT00725881,on the clinicaltrials.gov Website, ...
(Date:9/3/2008)... Md., Sept. 3 /- Panacea Pharmaceutic...ent Number 7,413,737 covering,antibodies against h...), a,proprietary human cancer biomarker and therap...ollaboration with the Massachusetts Institute of,T...de rights to this patent,for development of human ...
(Date:9/3/2008)...Company to Discuss Phase 3 Plans with FDA, PRINCE...ics, Inc.,announced today that it successfully co... of the company,s new, innovative low-dose, once-w...rs to by its internal product,code AG-200-15. The ...t its,primary endpoint of ovulation suppression, c...
(Date:9/3/2008)...rial Reconfirms Strong Evidence Pycnogenol(R) Lowe...ect on Joints Following Cessation ...3 /- According to the Center for,Dise... type of arthritis,is on the rise. A new study pu...arch, reveals Pycnogenol(R), bark extract from the...
Breaking Medicine Technology:Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Stimuvax 28R 29 Phase II data highlight three year survival results for patients with non small cell lung cancer 376 1Stimuvax 28R 29 Phase II data highlight three year survival results for patients with non small cell lung cancer 376 2Stimuvax 28R 29 Phase II data highlight three year survival results for patients with non small cell lung cancer 376 3Stimuvax 28R 29 Phase II data highlight three year survival results for patients with non small cell lung cancer 376 4Cardicas C Port 28R 29 Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed Chest Heart Bypass Surgeries 371 1Cardicas C Port 28R 29 Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed Chest Heart Bypass Surgeries 371 2Cardicas C Port 28R 29 Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed Chest Heart Bypass Surgeries 371 3Cardicas C Port 28R 29 Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed Chest Heart Bypass Surgeries 371 4R P Simmons Family Foundation Pledges 242 Million for New Childrens Hospital of Pittsburgh of UPMC Campus 530 1R P Simmons Family Foundation Pledges 242 Million for New Childrens Hospital of Pittsburgh of UPMC Campus 530 2Medarex Announces Extension of Broad Antibody Development Relationship with Centocor 369 1Medarex Announces Extension of Broad Antibody Development Relationship with Centocor 369 2Medarex Announces Extension of Broad Antibody Development Relationship with Centocor 369 3
...Lymphoma Reported,Today at ASCO Annual Meeting, PH...thKline plc,announced today long-term efficacy dat...e of frontline treatment with the BEXXAR(R),Therap...momab) in,76 patients with newly diagnosed advance...gimen was found to induce durable clinical,and mol...
...e/ -- (SEND2PRESS,NEWSWIRE) -- Epeius Biotechnolog... a historic landmark in medical oncology and a,def...gene therapy.,The first clinical report of its kin...ue of the International Journal of,Oncology, Vol.3...res of tumor destruction observed in chemo-resista...
Other Medicine Technology:8-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 28-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 38-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 58-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 7News from the Battlefield of Metastatic Cancer: Epeius,Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G),from the Stone of Chemistry and Physics 2News from the Battlefield of Metastatic Cancer: Epeius,Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G),from the Stone of Chemistry and Physics 3
Tank Blotting System. Designed for Western, Northern, or Southern Blotting. Transfer up to three gels with dimensions as large as 15cm x 21.5cm. Includes and internal cooling base for temperature
... proven electrophoretic transfer apparatus incorpo...ltimate in field uniformity. Its design allows for... when coupled with a low voltage power source such...ts/cm. The result is exceptionally rapid and exact...
...lot cell, a component of Bio-Rad's modular mini el...resis Systems), provides rapid, high-quality blott...ransfers two 7.5 x 10 cm gels in just 1 hour. Cool... absorbs heat generated during transfers. The Mini...
Includes PowerPac 200 power supply. Flexibility for a Range of Parameters. Quantitative Transfers. Native Enzyme, High Intensity, or Overnight Transfers. Faster, Higher-Efficiency Transfers via Pl
Medicine Products: